Monday, October 5, 2026

Tech Sector

3 articles

Alphabet Raises 2026 Capex Guidance as Cloud Capacity Stays Supply-Constrained

Alphabet Raises 2026 Capex Guidance as Cloud Capacity Stays Supply-Constrained

Alphabet lifted its 2026 capital expenditure outlook after CFO Anat Ashkenazi said Google Cloud remains supply-constrained for a multiple consecutive quarters. The move puts Alphabet inside a roughly $650 billion 2026 spending envelope shared by four AI hyperscalers, raising the stakes for investors weighing capex against returns.

LM Salvado•
TSMC Lifts 2026 Capex Target After Record Q2, Boosting Equipment Makers

TSMC Lifts 2026 Capex Target After Record Q2, Boosting Equipment Makers

TSMC raised its 2026 capital spending target on July 16 after posting record second-quarter results, signaling sustained AI chip demand. Semiconductor equipment supplier Applied Materials is already up 121% year-to-date, and analysts are watching whether ASML and Lam Research follow the same trajectory.

LM Salvado•
AI Cloud Providers Pivot to Self-Built Data Centers as Infrastructure Bottlenecks Replace Chip Shortages

AI Cloud Providers Pivot to Self-Built Data Centers as Infrastructure Bottlenecks Replace Chip Shortages

CoreWeave and other specialized AI cloud providers are developing in-house data center construction capabilities as powered shell infrastructure has become the primary deployment constraint, not chip availability or power access. The shift marks a vertical integration push aimed at cutting deployment delays, with CoreWeave expecting to resolve the majority of current backlogs by Q1 2026.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com